GSK1324726A_1300031-52-0_DataSheet_MedChemExpress
进口药品注册标准目录2
甘氨酸 固体脂肪36型 固体脂肪38型 共聚维酮 H 黄凡士林 滑石粉
糊精
药品生产企业使用药用辅料调查情况汇总表
镇江市环宇药用辅料厂 海盐六和淀粉化工有限公司 嘉兴市白浪淀粉制品有限公司 华北制药康欣有限公司 安徽山河药用辅料有限公司 河南精忠威尔药业有限公司 J 甲基丙烯酸-丙烯酸乙酯 Rohm GmbH & Co.KG （德国进口） 共聚物水分散体 甲基丙烯酸共聚物A型 Rohm GmbH & Co.KG （德国进口） 聚维酮K30 湖州展望药业有限公司 BASF Corporation （美国进口） 安徽山河药用辅料有限公司 博爱新开源制药有限公司 海南南杭药业有限公司 聚山梨酯80（吐温80） 南京威尔化工有限公司 上海申宇医药化工有限公司 龙游聚兴粮油医药化工有限公司 北京市海淀会友精细化工厂 南京威尔化工有限公司 辽阳奥克纳米材料有限公司 北京海淀会友精细化工厂 上海浦东高南化工厂 南京威尔化工有限公司 International Specialty Products Inc. （ 美 国进口） 连云港华瑞化工有限责任公司 INTERNATIONAL SPECIALTY PRODUCTS INC.（美国进口） 苏卫药准字（94）第3022-2号 浙卫药准字（1998）第220902号 浙卫药准字（1996）第220901号 冀卫药准字（1995）第000057号 皖药准字（2002）第F0001号 豫药准字F20040002号 进口药品注册证号：H20060013 进口药品注册证号：H20060593 浙药准字F20060062号 进口药品注册证号：H20040430 皖药准字F20060001 （95）卫药准字F-01号 琼药准字F20040001 苏卫药准字（2001）第423201号 沪卫药准字（1995）第186001号 浙卫药准字（1996）第184101号 京卫药准字（95）第023号 苏卫药准字（2001）第423301号 辽药准字F（2004）第900033号 京卫药准字（95）第008号 沪卫药准字（1995）第105004号 苏卫药准字（2001）第423601号 进口药品注册证号：H20030492 苏卫药准字（1983）第308001号 进口药品注册证号：H20030278 第 3 页 《中国药典》2005年版二部 《中国药典》2005年版二部 《中国药典》2005年版二部 《中国药典》2005年版二部 《中国药典》2005年版二部 《中国药典》2005年版二部 进口药用辅料注册标准 JX20020020 进口药品注册标准 JX20020322 《中国药典》2005年版二部 进口药品注册标准 JX20030277 《中国药典》2005年版二部 《中国药典》2005年版二部 《中国药典》2005年版二部 《中国药典》2005年版二部 《中国药典》2005年版二部 《中国药典》2005年版二部 《中国药典》2005年版二部 《中国药典》2005年版二部 《中国药典》2005年版二部 《中国药典》2005年版二部 《中国药典》2005年版二部 《中国药典》2005年版二部 进口药品注册标准 JX20020325 《中国药典》2005年版二部 进口药品注册标准 JX19990242
MG-132_DataSheet_MedChemExpress
Inhibitors, Agonists, Screening Libraries Data SheetBIOLOGICAL ACTIVITY:MG–132 is a potent, non–specific 20S proteasome inhibitor, with IC 50 of 24.2 nM for the β5 chymotrypsin –like active site.IC50 & Target: IC50: 24.2 nM (chymotrypsin–like activity)[1]In Vitro: Dose–dependent inhibition of cell growth is observed in HeLa cells with an IC 50 of approximately 5 μM MG132 for 24 h.MG132 inhibits the growth of HeLa cells via inducing the cell cycle arrest as well as triggering apoptosis [2]. MG–132 inhibits C6glioma cell proliferation in a time– and dose–dependent manner (the IC 50 value at 24 h is 18.5 μM). MG–132 (18.5 μM) suppresses the proteasome activity by about 70% at 3 h. MG–132 induces apoptosis via down–regulation of antiapoptotic proteins Bcl–2 and XIAP, up–regulation of pro–apoptotic protein Bax and caspase–3, and production of cleaved C–terminal 85 kDa PARP. MG–132 also causes a more than 5–fold increase of reactive oxygen species [3]. The IC 50 of MG–132 against HeLa, CaSki, and C33A cervical cancer cells viability after 48 h of incubation is 2.1, 3.2, and 5.2 μM, respectively [4].In Vivo: The in vivo antitumor activity of MG–132 against cervical cancer is examined using s.c. xenograft models. MG–132 is injected at 1 mg/kg using the following schedule: days 1, 4, 8, 12, 15 18, 23, and 26 for mice bearing HeLa tumors. The growth inhibition rates of MG132 compared to control is 49%[4]. MG–132 (i.p., 0.1 mg/kg/day) attenuates pressure–overload–induced cardiac hypertrophy and improves cardiac function in abdominal aortic banding (AAB) rats through regulation of ERK1/2 and JNK1signaling pathways [5].PROTOCOL (Extracted from published papers and Only for reference)Kinase Assay:[3]After growing on six–well plates (3×105 cells/well) for 24 h, C6 glioma cells are treated with either PBS (control) or 18.5 μM MG–132 for 3, 6, 12, or 24 h at 37°C. Cells are thoroughly scraped from the culture dishes with a cell scraper and washed with cold PBS. After centrifugation for 10 min at 800×g, the cell pellets are suspended in ice–cold buffer (50 mM Tris–HCl, pH 7.5, 20μM ATP, 5 mM MgCl 2, 1 mM dithiothreitol, and 20% glycerol) and homogenized with a Pyrex glass microhomogenizer (20 strokes).The homogenate is centrifuged at 15 000×g for 10 min at 4°C to obtain supernatant. Protein concentration is determined using protein assay kits. A total of 10 μL (1 μg/μL) of each freshly made supernatant is incubated in a 96–well plate at 37°C for 30 min with 10 μL of 300 μM of Succinyl–LLVY–AMC and 85 μL of assay buffer (20 mM Tris–HCl, pH 7.5, and 20% glycerol). Release of fluorescent AMC is measured with a spectrofluorometer at 440 nm with an excitation wavelength of 380 nm [3].Cell Assay: MG–132 is dissolved in PBS to a storage concentration of 50 μM [3]. [3]C6 glioma cells are seeded onto 96–well microplates (3×104 cells/well) and cultured for 24 h. The cells are treated with PBS or MG–132 final concentrations of 10, 20, 30, and 40 μM,respectively. Cell viability is assessed using an MTT assay at 3, 6, 12, and 24 h after MG–132 treatment. The absorbance value at 570nm is read using an automatic multi–well spectrophotometer. C6 glioma cells (3×105 cells/well) are allowed to grow on coverslips in 6–well culture plates for 24 h. The cells are then treated with either PBS (control) or 18.5 μM MG–132 at 37°C for 24 h. Cells growing on glass coverslips are fixed in methanol for 5 min at room temperature. The fixed cells are washed twice with PBS and then incubated with Hoechst 33342 for 5 min at room temperature and observed under a fluorescence microscope. Fragmented orProduct Name:MG–132Cat. No.:HY-13259CAS No.:133407-82-6Molecular Formula:C 26H 41N 3O 5Molecular Weight:475.62Target:Proteasome Pathway:Metabolic Enzyme/Protease Solubility:10 mM in DMSOcondensed nuclei are scored as apoptotic[3].Animal Administration: MG–132 is dissolved in vehicle (saline) (Mice)[4].MG–132 is dissolved in vehicle (0.1% DMSO) (Rat)[5].[4][5]Mice[4]C.B–17/lcr–scid/scidJcl mice are inoculated s.c. with HeLa, CaSki, or C33A (1×107 cells). Tumors are allowed to grow for 1 week. Mice are killed and tumors are removed. Tumors are then cut into 2–mm diameter pieces and s.c. transplanted inC.B–17/lcr–scid/scidJcl mice (n=6 per group). One week after inoculation, mice are treated with i.v. injection of saline (control),MG–132 (1 mg/kg/dose) twice a week for 4 weeks. The volume (V) of tumors is measured before every injection, as estimated using equation V=a×b2/2 where a and b are major and minor axes of the tumor measured by a caliper, respectively.Rat[5]Male Sprague–Dawley rats (8 weeks old, 180–230 g) are used to establish pressure–overload model. All animals are separated into four groups (10 rats per group): (i) vehicle–treated sham group; (ii) MG–132–treated sham group; (iii) vehicle–treated abdominal aortic banding (AAB) group; and (iv) MG–132–treated AAB group. Under intraperitoneal pentobarbital (50 mg/kg) anesthesia, AAB is created using a 5–0 suture tied twice around the abdominal aorta in which a 21–gauge needle is inserted. The needle is then retracted yielding a 70–80% constriction with an outer aortic diameter of ~0.8 mm. In the sham surgery rats, the same surgery is performed except the aorta is constricted. At Day 3 after the surgery, MG–132–treated rats are intraperitoneally injected with 0.1 mg/kg/day of MG–132 for 8 weeks. All control animals are injected with a corresponding volume of vehicle only (0.1% DMSO).References:[1]. Braun HA, et al. Tripeptide mimetics inhibit the 20 S proteasome by covalent bonding to the active threonines. J Biol Chem. 2005 Aug 5;280(31):28394–401.[2]. Han YH, et al. The effect of MG132, a proteasome inhibitor on HeLa cells in relation to cell growth, reactive oxygen species and GSH. Oncol Rep. 2009 Jul; 22(1):215–21.[3]. Fan WH, et al. Proteasome inhibitor MG–132 induces C6 glioma cell apoptosis via oxidative stress. Acta Pharmacol Sin. 2011 May;32(5):619–25.[4]. Matsumoto Y, et al. Enhanced efficacy against cervical carcinomas through polymeric micelles physically incorporating theproteasome inhibitor MG132. Cancer Sci. 2016 Jun;107(6):773–81.[5]. Chen B, et al. MG132, a proteasome inhibitor, attenuates pressure–overload–induced cardiac hypertrophy in rats by modulation of mitogen–activated protein kinase signals. Acta Biochim Biophys Sin (Shanghai). 2010 Apr;42(4):253–8.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
UPLC-DAD波长切换法同时测定复方红衣补血口服液中6种多酚类化合物的含量
中图分类号:Ｒ ９２１ ２ 文献标识码:Ａ 文章编号:１００９ － ３６５６(２０２１)０３ － ０２８３ － ０６
ｄｏｉ:１０ １９７７８ / ｊ ｃｈｐ ２０２１ ０３ ０１８
Ｓｉｍｕｌｔａｎｅｏｕｓ ｄｅｔｅｒｍｉｎａｔｉｏｎ ｏｆ ｓｉｘ ｐｏｌｙｐｈｅｎｏｌｓ ｉｎ Ｃｏｍｐｏｕｎｄ Ｈｏｎｇｙｉ
３０、４３ ｎｇ ｍＬ － １ ꎻ 精 密 度、 稳 定 性、 重 复 性 试 验 的 ＲＳＤ 均 小 于 ２ ０％ ꎻ 平 均 加 样 回 收 率 分 别 为 ９８ ５６％
( ＲＳＤ ＝ ２ ２６％ ꎬｎ ＝ ９ ) 、 ９７ ９４％ ( ＲＳＤ ＝ １ ５４％ ꎬ ｎ ＝ ９ ) 、 ９７ ２３ ％ ( ＲＳＤ ＝ ２ １９％ ꎬ ｎ ＝ ９ ) 、 ９８ ５４％
摘要 目的: 建立超高效液相色谱￣ＤＡＤ 波长切换法同时测定复方红衣补血口服液中咖啡酸、没食子酸、对
羟基肉桂酸、阿魏酸、儿茶素、表儿茶素含量的方法ꎮ 方法:采用高效液相色谱法ꎮ 色谱柱为 Ｗａｔｅｒｓ Ｓｙｍｍｅ￣
ｔｒｙ Ｃ１８ (４ ６ ｍｍ × １５０ ｍｍꎬ３ ５ μｍ) ꎬ流动相为甲醇￣０ １％ 甲酸溶液( 梯度洗脱) ꎬ流速为 ０ ５ ｍＬｍｉｎ － １ ꎬ检测
２ 方法与结果
２ １ 色谱条件与系统适用性
色谱 柱: Ｗａｔｅｒｓ Ｓｙｍｍｅｔｒｙ Ｃ１８ ( ４ ６ ｍｍ × １５０
的质量研究是以儿茶素 [１０] 、白藜芦醇 [１１] 单一成分
ｍｍꎬ３ ５ μｍ) ꎻ 流 动 相: 甲 醇 ( Ａ) ￣０ １％ 甲 酸 溶 液
定ꎮ 本研究建立 ＵＰＬＣ 法同时测定复方红衣补血口
美国贝克曼库尔特流式细胞分析仪
美国贝克曼库尔特流式细胞分析仪（Beckman coulter cell）产品型号：Cell Lab Quanta SC当前价格：0.00元产品数量：0新旧程度：全新有效期至：0000-00-00所在地：产品简介：仪器简介：T细胞亚群检测的CD45/CD4/CD8/CD3、CD45/CD56/CD19/CD3；阵发性血红蛋白尿（PNH）检测的CD55、CD59；血小板无力症（GT）检测的CD41、CD61等等详细信息仪器简介：T细胞亚群检测的CD45/CD4/CD8/CD3、CD45/CD56/CD19/CD3；阵发性血红蛋白尿（PNH）检测的CD55、CD59；血小板无力症（GT）检测的CD41、CD61等等。
但对于白血病/淋巴瘤免疫分型，国际上迄今为止也没有统一的抗体组合。
在2000年国际细胞分析学会（ISAC）大会上，临床血细胞计数协会组织了一次国际专家会议，以期对检测血液淋巴系统肿瘤所需最少、最有效的单抗数达成共识。
75%与会者一致认为，对于慢性淋巴系统增殖性疾病（CLD）有9种单抗：CD5,CD19,κ,λ,CD3,CD20,CD23,CD10,CD45对初诊来说是最基本的。
淋巴瘤和CLD相似，需要至少12-16种单抗。
对于急性白血病（AL），75%的与会者认为大约13-15种单抗是最基本的：CD10,CD19,CD79a,CD13,CD33,CD34,CD45,CD2,MPO，CD7,CD14,CD3,HLA-DR等，对初步鉴别白血病系列是必需的。
其他一些（CD16,CD56,CDw65,TdT,cyCD3）可能对某些病例有用。
几乎所有的投票者都认为，要对急性白血病完善分类所需单抗的恰当数量平均为20-24种。
但这些抗体之间组合也是一大难题，目前也无统一规定（如表二）。
大会多数发言者(11/13)指出，对已确诊病人的监护和分期来说，仅需较少单抗。
抗体的质量控制是实验的关键环节。
抗体的质量包括其特异性、灵敏度、精密度。
GSK1324726A_SDS_MedChemExpress
Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:May-24-2017Print Date:May-24-20171. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :GSK1324726ACatalog No. :HY-13960CAS No. :1300031-52-01.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureGHS Classification in accordance with 29 CFR 1910 (OSHA HCS)Acute toxicity, Oral (Category 4),H302Acute aquatic toxicity (Category 1),H400Chronic aquatic toxicity (Category 1),H4102.2 GHS Label elements, including precautionary statementsPictogramSignal word WarningHazard statement(s)H302 Harmful if swallowed.H410 Very toxic to aquatic life with long lasting effects.Precautionary statement(s)P264 Wash skin thoroughly after handling.P270 Do not eat, drink or smoke when using this product.P273 Avoid release to the environment.P301 + P312 IF SWALLOWED: Call a POISON CENTER or doctor/ physician if you feel unwell.P330 Rinse mouth.P391 Collect spillage.P501 Dispose of contents/ container to an approved waste disposal plant.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:I⁻BET726; GSK 1324726A; GSK⁻1324726A; I⁻BET 726Formula:C25H23ClN2O3Molecular Weight:434.91CAS No. :1300031-52-04. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Powder-20°C 3 years4°C 2 yearsIn solvent-80°C 6 months-20°C 1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance Light yellow to yellow (Solid)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGUN number: 3077Class: 9Packing group: IIIEMS-No: F-A, S-FProper shipping name: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.Marine pollutant: Marine pollutant.IATAUN number: 3077Class: 9Packing group: IIIProper shipping name: Environmentally hazardous substance, solid, n.o.s.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2017 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
反相高效液相色谱法测定化妆品或洗涤用品中对氯二甲苯酚、三氯卡班和三氯生
#" 结果与讨论
# ! !" 实验条件的选择 , , 资料检索［ $ ］及实验表明， 以乙腈与水或甲醇与水按不同 比例混合作 流 动 相 时， 三氯卡班和三氯生不能达到基线分 离， 即使采用梯度法， 也无济于事［ ! ］。经试验， 本方法选择四 氢呋喃 + 水 （ 体积比为 %". #" ） 作流动相可同时测定对氯二甲 苯酚、 三氯卡班和三氯生， 三组分获得很好的分离。 # ! #" 线性关系与检出限 , , 按上述色谱条件 分 别 注 入 系 列 质 量 浓 度 的 混 合 标 准 溶 测定峰面积， 以氯二 甲 苯 酚、 三氯卡班和三氯生 液各 $" ! D ， 的质量浓度 ! （ %G E D ） 对相应 的 峰 面 积 " 作 图， 三 者 均 在 $" / !"" %G E D 范围内与其各 自 对 应 的 峰 面 积 呈 线 性 关 系。 其 线性回归方程分别为 " # $( !"" ! H $+ &"" （ $ I "- ’’’ ’& ） ， " # +" #"" ! J # ($" （ $ I "- ’’’ #! ） 和 " I !# &"" ! H (# #"" （$ I "- ’’’ ’) ） 。经实验测定，对氯二甲苯酚、 三氯卡班和三 氯 生的最低检测量 （ % & ’ I (） 分 别 为 $， "- $ 和 $ 6G ， 最低检测 分别为 "- $ ， "- "$ 和 "- $ %G E D 。 质量浓度 （ % & ’ I (） # ! $" 精密度及回收率试验 , , 将混合标准溶液在进样量为 "- & ， $- & ! G 两 个 不 同 质 量 得 到 对 氯 二 甲 苯 酚、 三氯卡班和三氯生 水平下各进样 % 次， 峰面积的 相 对 标 差 偏 差 （ KAL ） 分 别 为 "- $" ， "- $& ， "- $) 及
GSK1324726A_I-BET726_BET蛋白抑制剂_CAS号1300031-52-0_M9146说明书_AbMole中国
分子量434.91溶解性（25°C）DMSO ≥ 43 mg/mL分子式C25H23ClN2O3Water InsolubleCAS号1300031-52-0Ethanol储存条件3年 -20°C 粉末状生物活性GSK1324726A（I-BET726）是一种有效的选择性BET蛋白抑制剂，对BRD2，BRD3和BRD4的IC50值分别为41 nM，31 nM和22 nM。
GSK1324726A在神经母细胞瘤细胞系中，有效抑制细胞生长并诱导细胞毒性。
体内研究中，在小鼠SK-N-AS和CHP-212模型中，GSK1324726A(15 mg/kg, p.o.)抑制肿瘤生长，并下调MYCN和BCL2的表达。
在小鼠感染性休克模型中，GSK1324726A (10 mg/kg, i.v.)表现出有效的抗炎作用。
实验操作来自于公开的文献，仅供参考细胞实验细胞系方法浓度处理时间动物实验动物模型Xenograft models of non-MYCN-amplified and MYCN-amplified neuroblastoma in immunocompromised mice using the SK–N-AS and CHP-212 cell lines配制Suspended in 1% methylcellulose剂量15 mg/kg once daily给药处理p.o.不同实验动物依据体表面积的等效剂量转换表（数据来源于FDA指南）小鼠大鼠兔豚鼠仓鼠狗重量 (kg)0.020.15 1.80.40.0810体表面积 (m)0.0070.0250.150.050.020.5K系数36128520动物 A (mg/kg) = 动物 B (mg/kg) ×动物 B的K系数动物 A的K系数例如，依据体表面积折算法，将白藜芦醇用于小鼠的剂量22.4 mg/kg 换算成大鼠的剂量，需要将22.4 mg/kg 乘以小鼠的K系数（3），再除以大鼠的K系数（6），得到白藜芦醇用于大鼠的等效剂量为11.2 mg/kg。
蛋白核酸样品制备-bio-rad产品介绍
Quantum Prep质粒中型制备试剂盒采用了简便的离心柱操作流程，显著地缩短了大量质粒DNA制备所需的时间，所制备的DNA可用于转染、亚克隆和其它酶处理。
Chelex树脂
Bio-Rad提供两种以Chelex为基质的树脂，用于从多种粗样品(如血液、细菌、组织和头发)中抽提DNA。由于所抽提的DNA通常用于下游的PCR，因此它必须不含能抑制扩增反应的金属离子，Chelex由成对的亚氨基二乙酸离子结合在苯乙烯二乙烯苯基质上形成，对多价阳离子具有很强的选择性，从而有效地去除这类污染杂质。
■■哺乳动物、植物、酵母、微生物样品的细胞裂解和蛋白抽提实验方法
■■该试剂盒能使用于任何特殊种类的蛋白提取，不仅局限于下游MicroRotofor等电聚焦
■■试剂盒抽提的蛋白样品结果，不必再改变缓冲液条件，而能迅速使用MicroRotofor进行等电聚焦实验。
ReadyPrep小研磨试剂盒
Readyprep mini grinders研磨处理小量生物样品，对于核酸和蛋白质具有极高的回收率，每个小研磨棒( minigrinders )包括1.5ml含研磨树脂的研磨管和相应的研磨杵，研磨树脂是一种中性强张力的微粒状研磨剂，不与蛋白质和核酸结合。Readyprep mini grinders是一次性使用的试剂盒，并且不含有核酸酶或蛋白酶，他们也是MicroRotofor裂解试剂盒(哺乳动物)的组成成分，可以分开单独出售，每20个为一个包装，mini grinders具有以下特性：
Aurum质粒小型制备试剂盒能为ቤተ መጻሕፍቲ ባይዱ下领域的研究制备高产量重现性高的质粒DNA：
■■全自动荧光测序
■■限制性酶切
■■连接和转化
■■转染